Caplacizumab induces fast and durable platelet count responses with improved time to complete remission and recurrence-free survival in patients with acquired thrombotic thrombocytopenic purpura

• L. Kaynar,
• P. Coppo,
• M. Scully,
• J. De La Rubia,
• F. Peyvandi,
• S. Cataland,
• J. A. Kremer Hovinga,
• P. Knoebl,
• K. Pavenski,
• J. Minkue Mi Edou,
• F. Callewaert,
• R. De Passos Sousa

Affiliations

L. Kaynar

Erciyes University, Kayseri, Turkey; Corresponding author.

P. Coppo

Saint-Antoine University Hospital, AP-HP, Paris, France

M. Scully

National Institute for Health Research UCLH-UCL Biomedical Research Center, London, United Kingdom

J. De La Rubia

Catholic University of Valencia and Hospital Doctor Peset Valencia, Valencia, Spain

F. Peyvandi

Università degli Studi di Milano, Milan, Italy

S. Cataland

The Ohio State University, Columbus, OH, United States

J. A. Kremer Hovinga

Bern University Hospital, University of Bern, Bern, Switzerland

P. Knoebl

Medical University of Vienna, Vienna, Austria

K. Pavenski

St. Michael's Hospital and University of Toronto, Toronto, ON, Canada

J. Minkue Mi Edou

Ablynx, a Sanofi Company, Zwijnaarde, Belgium

F. Callewaert

Sanofi, Diegem, Belgium

R. De Passos Sousa

Sanofi, Lisbon, Portugal